SPATA31C1

Across TCGA pan-cancer cohorts, SPATA31C1 RNA is linked to patient survival in 15 of 34 cancer types, making it the most broadly survival-associated SPATA31C1 data layer compared with 10 for mutation status.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher SPATA31C1 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated SPATA31C1 expression acts as an unfavorable survival marker, although some lineages such as BLCA and THYM show a favorable association.

LIHC, KICH, and DLBC are the cancer types where SPATA31C1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	All	0.300	0.541	<.001	105	view →
KICH	OS	Tertile	III,IV	0.178	0.761	.001	60	view →
DLBC	OS	Tertile	III,IV	0.175	0.874	.025	36	view →
BLCA	DFS	Tertile	IV	0.862	0.278	.011	24	view →
SKCM	DFS	Tertile	III,IV	0.486	0.636	.019	18	view →
KIRC	DFS	Tertile	IV	0.230	0.513	.039	18	view →
LUAD	OS	Tertile	IV	0.114	0.560	.038	18	view →
CHOL	OS	Tertile	III,IV	0.275	0.886	.045	18	view →
THYM	OS	Median	All	1.000	0.921	.012	10	view →
PCPG	DFS	Tertile	All	0.438	0.920	.003	9	view →
UCEC	OS	Quartile	All	0.892	0.934	.031	8	view →
LUSC	DFS	Tertile	All	0.283	0.430	.033	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 15 lineages.

SPATA31C1–LIHC (OS)

Open the LIHC breakdown →